Ampion effective in study, Ampio shares soar


Ampio Pharmaceuticals (AMPE) soars 34% premarket after saying the endogenous immunomodulatory molecule Ampion met its primary endpoint in a study evaluating the treatment's ability to reduce pain in patients with osteoarthritis of the knee.

Orthopedic surgeon Dr. Brian McGrath, the study's principal investigator, calls the results "fantastic" and notes that it "may soon be possible to offer OAK patients an effective [injectable] therapy." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs